Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$1.50 ▼ -0.10
(-6.25%)
MKT CAP: $26.4M • VOL: 78.4K
52W L $1 52W H $8
ROARABLE / RQD
D- • 39/100
PIOTROSKI
3 / 9
CVM // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-09-30 | FY 2024
FILED 2024-09-30 | FY 2023
FILED 2023-09-30 |
|---|---|---|---|
| Revenue (Total Sales) | $0 | $0 | $0 |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$24.8M | -$26.4M | -$31.5M |
| Operating Margin % | — | — | — |
| Net Income (GAAP) | -$25.4M | -$26.9M | -$32.4M |
| EBITDA (Normalized) | -$24.8M | -$26.3M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$17.1M | -$18.8M | -$22.8M |
| Capital Expenditures (CapEx) | $38.1K | $94.9K | — |
| Free Cash Flow (FCF) | -$17.2M | -$18.9M | -$22.8M |
| FCF Margin % | — | — | — |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | — | — | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $11.1M | $11.3M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR CVM.